-
BOE-Backed Genewise Bio Secures RMB 100 Million in Series A Financing for Molecular Diagnostics
•
Genewise Bio, a molecular diagnostics company nurtured by BOE Technology Group, has reportedly secured RMB 100 million in a Series A financing round. Tsing Song Capital led the investment round, with additional investments from Wuhe Capital, Aeonmed, and Pinnacles Medtech. Established in 2021, Genewise Bio has developed a comprehensive independent…
-
Lucy Therapeutics Boosts CNS Disease Research with USD 12.5 Million in Additional Financing
•
Lucy Therapeutics Inc., a U.S.-based developer of small-molecule drugs for central nervous system (CNS) diseases, has raised an additional USD 12.5 million in financing. The company is jointly incubated by China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873). Existing investors Engine Ventures and Safar Partners spearheaded the funding…
-
Fosun Pharma Rumored to Fully Acquire Subsidiary Henlius Pharmaceutical, Shares Suspended
•
Rumors are circulating, as reported by Bloomberg citing insiders, that Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) is planning to fully acquire its subsidiary Shanghai Henlius Biotech Co., Ltd (HKG: 2696). This strategic move comes as Henlius, a Hong Kong-listed company, has suspended its shares from trading…
-
IVD Medical Holding Ltd Enters Non-Binding MoU with Chinese Chemiluminescence IVD Company for Potential Collaboration
•
IVD Medical Holding Ltd (HKG: 1931), a leading in vitro diagnostic (IVD) company based in China, has announced the signing of a non-binding Memorandum of Understanding (MoU) with a fellow Chinese IVD company, which is yet to be named. The MoU outlines the intention to explore potential collaboration opportunities, including…
-
Bayer’s Consumer Health Division to Invest $83 Million in New Supply Center in China
•
Bayer (ETR: BAYN)’s Consumer Health Division has entered into an agreement with Qidong city in Jiangsu province to establish a new supply center. The German multinational pharmaceutical company will invest RMB 600 million (USD 83 million) in the initial phase of the project, with the facility expected to become operational…
-
Beijing’s Cipher Gene Secures RMB 100 Million in Series C Financing to Expand Precision Medicine Services
•
Cipher Gene, a Beijing-based gene big data and precision medicine service provider, has reportedly secured RMB 100 million in a Series C financing round. The funding round was led by Chengdu Jinjiang, with participation from Zhongxi Fund and several existing investors. The capital raised will be utilized to enhance the…
-
Blue Sail Medical Subsidiary Secures RMB 100 Million Investment to Expand Operations
•
China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced that Blue Sail Biosensors Medical Technology, its wholly-owned subsidiary, has introduced a strategic investor, Beijing Daxing Airport Economic Zone Development Fund. The fund has made a substantial investment of RMB 100 million (USD 14 million) in the company. The proceeds…
-
Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced a comprehensive strategic partnership with the UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). This collaboration will encompass the entire spectrum of drug development, including small molecules, macromolecules, and gene therapies, from…
-
Pharmaron to Sell Proteologix Stake in Upcoming Johnson & Johnson Acquisition
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced the sale of its 10.21% stake in Proteologix, a US-based specialist in immune-mediated diseases. The acquisition of Proteologix is set to be completed by healthcare giant Johnson & Johnson (J&J; NYSE:…
-
Zhejiang Huahai Pharmaceutical Co., Ltd Plans Capital Raise for Digital Manufacturing Expansion
•
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a leading Chinese pharmaceutical company, has unveiled plans for a private placement of 148,000,000 shares, raising a total of RMB 1.21 billion (approximately USD 170 million). The capital raised from this private placement is earmarked for the construction of digital intelligent manufacturing facilities…
-
GE HealthCare Partners with Shanghai Pudong for USD 52.5 Million Medical Tech Investment
•
GE HealthCare (NASDAQ: GEHC), a leading medical technology firm, has entered into a cooperation intent letter with the Pudong district of Shanghai, committing an investment of RMB 380 million (USD 52.5 million). This strategic partnership will focus on the introduction of new products, construction of new production lines, green factory…
-
Vision Medicals Raises Hundreds of Millions in Series D+ Round to Advance Molecular Diagnostics
•
Guangdong-based Vision Medicals has reportedly secured hundreds of millions of renminbi in a Series D+ financing round, led by Kequan Investment with participation from Tianxin Fund. The funds raised will be directed towards accelerating the research and development of precision diagnosis products focused on pathogenic molecules. Additionally, the company plans…
-
Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets
•
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ: AZN), Bristol Myers Squibb (BMS; NYSE: BMY), and Takeda (NYSE: TAK). These partnerships underscore the biotech company’s commitment to leveraging its integrated AI and wet-lab technologies for the design of conformation- and target-selective antibody candidates.…
-
Elite (Suzhou) Analytical Instruments Boosts Liquid Chromatography Push with Series A+ Round
•
China-based Elite (Suzhou) Analytical Instruments Co., Ltd, a premier manufacturer of liquid chromatography devices in the nation, has reportedly secured nearly RMB 100 million (USD 13.8 million) in a Series A+ financing round. The funding round was co-led by GT (Shanghai) Equity Investment Fund and Guotai Junan Innovation Investment, with…
-
Bayer’s Q1 2024 Report Shows Slight Dip in Sales Amid Pharmaceutical Unit’s Growth
•
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2024, showing a slight 0.6% year-on-year (YOY) decrease in group sales to EUR 13.8 billion (USD 14.9 billion), excluding portfolio and exchange rate effects. The pharmaceuticals business segment reported a 3.9% increase in sales, reaching EUR…
-
Novo Nordisk’s Bispecific Antibody Mim8 Achieves Milestone in Haemophilia A Trial
•
Novo Nordisk (CPH: NOVO-B), a pharmaceutical company based in Denmark, has announced that its bispecific antibody (BsAb) Mim8 has successfully met the primary endpoints in a late-stage trial for haemophilia A. The trial focused on the reduction of treated bleeding episodes, with once-weekly and once-monthly doses of Mim8 showing reductions…
-
Healingovation Raises Over RMB 60 Million in Pre-Series A++ Round for Aquablation Surgical Robot
•
Healingovation, a Beijing-based innovator in surgical robots and intelligent diagnostic and therapeutic equipment, has reportedly secured more than RMB 60 million (USD 8.3 million) in a pre-Series A++ financing round. The round was led by CD Capital, with participation from Legend STAR, and returning investors Shunwei Capital, Lilly Asia Ventures,…
-
Subtle Medical Inc Closes USD 10 Million Series B+ Round to Accelerate Global Expansion
•
Subtle Medical Inc, a medical imaging specialist and Stanford University spin-off, has reportedly raised close to USD 10 million in a Series B+ financing round. The financing was backed by investors including Shanghai-based Wenzhou Capital, Fusion Fund, ENVISIONX Capital, Bluerun Ventures, and other strategic partners across the Asia Pacific region.…
-
DSciLab, mRNA Pharma Startup, Bags RMB 100 Million in Angel Financing Led by Fosun Health
•
DSciLab Co., Ltd, a China-based mRNA pharmaceutical company nurtured by Fosun Health Capital, has announced the completion of an angel financing round worth RMB 100 million. The round was led by Fosun Health Capital, with participation from Shanghai Creation Investment. The funds will be directed towards the advancement of core…
-
Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization
•
US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter of 2024, with global net sales remaining flat year-on-year (YOY) at USD 3.7 billion in constant currency terms. The base business brands experienced a 2% YOY decline to USD 2.3 billion, attributed to unfavorable channel…
